Evidence map›Paper›PMID 41709289›Full record

ArticleAlzheimer's research & therapy2026

Genetic validation of ABI3 p.Ser209Phe variant and its effects on early brain pathology in asymptomatic elderly individuals.

Mikko Koivumäki, Henna Martiskainen, Mari Takalo, Jenni Lehtisalo, Tiia Ngandu, FinnGen, Anniina Snellman, Mikko Hiltunen, Juha O Rinne

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Aberrant phase separation from a rare ABI3 mutation drives microglial dysfunction and Alzheimer's risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mikko Koivumäki *Turku PET Centre, University of Turku, Turku, Finland. mikkkoi@utu.fi.
Henna Martiskainen *Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Mari TakaloInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Jenni LehtisaloDepartment of Public Health, Lifestyles and Living Environments Unit, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
Tiia NganduDepartment of Public Health, Lifestyles and Living Environments Unit, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
FinnGen
Anniina SnellmanTurku PET Centre, University of Turku, Turku, Finland.
Mikko Hiltunen *Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Juha O Rinne *Turku PET Centre, University of Turku, Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) has a strong genetic component, with APOE ε4 being the most established risk factor through its effects on beta-amyloid (Aβ) metabolism and microglial function. Recent genetic studies have also implicated microglial genes, such as the ABI3

methodsWe used FinnGen R12 data (> 500,000 individuals), including 8,490 ABI3

resultsABI3

conclusionsABI3

Indexed as

Adaptor Proteins, Signal TransducingAlzheimer DiseaseBrainCytoskeletal ProteinsAgedAged, 80 and overAniline CompoundsApolipoprotein E4BenzothiazolesCohort StudiesFemaleFinlandGenetic Predisposition to DiseaseGenotypeHumansMagnetic Resonance Imaging2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAdaptor Proteins, Signal TransducingAniline CompoundsApolipoprotein E4BenzothiazolesCytoskeletal ProteinsThiazolesABI3S209FAlzheimer’s diseaseAPOE ε4FinnGenMicrogliaPET imagingβ-amyloid-

Identifiers

PMID41709289
PMCPMC13023201

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.